Cite
Impact of metformin versus repaglinide on non-glucaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
MLA
Lund, Søren S., et al. Impact of Metformin versus Repaglinide on Non-Glucaemic Cardiovascular Risk Markers Related to Inflammation and Endothelial Dysfunction in Non-Obese Patients with Type 2 Diabetes. Jan. 2008. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3062..7570f13f91bb64a95c8f9651412f5e3c&authtype=sso&custid=ns315887.
APA
Lund, S. S., Tarnow, L., Stehouwer, C. D., Schalwwijk, C. G., Teerlink, T., Gram, J. B., Winther, K., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H.-H., & Vaag, A. A. (2008). Impact of metformin versus repaglinide on non-glucaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Chicago
Lund, Søren S, Lise Tarnow, Coen DA Stehouwer, Casper G Schalwwijk, Tom Teerlink, Jørgen Brodersen Gram, Kaj Winther, et al. 2008. “Impact of Metformin versus Repaglinide on Non-Glucaemic Cardiovascular Risk Markers Related to Inflammation and Endothelial Dysfunction in Non-Obese Patients with Type 2 Diabetes,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3062..7570f13f91bb64a95c8f9651412f5e3c&authtype=sso&custid=ns315887.